Why the study?
Does the small-molecule compound ML216 alleviate cardiac fibrosis in aging-associated or isoproterenol-induced models?
Population
In vitro and in vivo models of aging-associated or β-adrenoceptor agonist isoproterenol-induced cardiac…
Design
Preclinical
Authors
Loading...
ML216 represents a potential therapeutic candidate for treating age-related and isoproterenol-induced cardiac fibrosis by targeting the TGF-β1 signaling pathway.
Does the small-molecule compound ML216 alleviate cardiac fibrosis in aging-associated or isoproterenol-induced models?
ML216 represents a potential therapeutic candidate for treating age-related and isoproterenol-induced cardiac fibrosis by targeting the TGF-β1 signaling pathway.
Liu et al. (2026) studied this question.